They have been saying they will announce the next drug-conjugate in 2H15. I hope that hasn't changed. Seems like they are looking to 2016 now?
Where do you see that Cytrx is out of the Russell index? I just looked it up and I don't see anywhere that they have been deleted from any of the Russell global, 3000, or micro. Thanks
Thank you abbaman7 for stating facts and I'm totally with you on them they are great.
AS for b_hesford2000, for one thing please fill me in on an inaccuracy that I have typed above. I stated a fact. Look it up! And it's not me getting giddy over their divi increase. mos was up after hours and I was only posting accurate news in my own words. I am heavily invested in potash for your information.
Yes you are right about BPC if Belarus is willing. I shouldn't of said rejoin Canpotex but what I meant was to venture with Canpotex in some manner.
With Belarus signing a 5 year potash deal with China at current prices it would be wise for Uralkali to pull their heads out and rejoin Canpotex.
Innovation into Biofertilizers to Drive Potassium Chloride
Leading companies such as PotashCorp have made significant investments in the brownfield potash expansion projects
I think a company like BHP can come in a buy out a company like Mosaic or Agrium. Potash Corp's market cap is too large in my opinion. But now is the time for something like this to happen. Could push prices up and Potash would benefit from big time from it. I think between now and June something big will happen in this industry.
Doesn't the priced offering of US $500 million aggregate principal amount of 3.000 percent notes due April 1, 2025 savings more than offset the pre-tax deduction on the bottom line when they report earnings? High demand and making a deal with China even if it is at $315/tonne should help them meet the higher end of their guidance. Also, it still hasn't been announced how many tonnes of potash Belaruskali is selling to China. If they can't meet their capacity demand that puts pot in the driver seat.
Cytrx is going for FDA approval for Aldo and Dox as a second-line treatment not a firs-line treatment.